BerGenBio ASA   Report issue

For profit Phase 1 Phase 2
Founded: Bergen Norway (2007)

Organization Overview

First Clinical Trial
2014
NCT02488408
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BerGenBio ASA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 19